Clark W. Smith, Ph.D., co-founded Proteos in 2003 after retiring from Pharmacia as Senior Director of Global Research Site Operations. Dr. Smith is one of the founding officers of the American Peptide Society and has more than 85 publications in the field. Before his career in the pharmaceutical industry, he was a faculty member of the University of Illinois Medical School. Following service in Viet Nam he earned his Ph.D. in organic chemistry from the University of Arizona and completed a postdoctoral fellowship at Cornell University under the mentorship of Nobel Laureate, Vincent du Vigneaud.
Robert L. Heinrikson, Ph.D., co-founded Proteos in 2003 after retiring from Pharmacia where he lead scientific teams in several therapeutic areas, including Cardiovascular Diseases, Inflammatory Bowel Disease, HIV therapies, Central Nervous System Diseases, and Adhesion Biology. These efforts led to marketing of tipranavir, a protease inhibitor for treatment of AIDS patients, and the discovery of the beta-secretase target (BACE1) in Alzheimer's Disease. Dr. Heinrikson is an internationally recognized expert in the field of Protein Chemistry and has over 200 publications in peer-reviewed journals and a dozen patents related to various aspects of protein science. Dr. Heinrikson earned his Ph.D. from the University of Chicago where, following post-doctoral studies at the Rockefeller University in New York City and the MRC Laboratory of Molecular Biology in Cambridge, England, he rose to the rank of Full Professor in the Department of Biochemistry.
Al Darzins, Ph.D., serves as President of Proteos and brings significant scientific leadership, management and business development skills to Proteos from his previous biotechnology roles in the private and public sectors. Prior to joining Proteos in 2016, he was an R&D Director at the Gas Technology Institute (GTI) where he was responsible for leading GTI’s biotechnology-based research efforts in alternative energy and renewable fuels development. Previous to joining GTI, Dr. Darzins was a Research Manager in DuPont’s Biofuels group where he led a large pathway engineering and enzyme evolution group. Before DuPont, he was at the U.S Department of Energy’s (DOE) National Renewable Energy Laboratory (NREL) where he managed a multi-disciplinary team responsible for developing next generation biofuels from lignocellulosic and microalgal biomass. He currently serves as a board member of the Algae Biomass Organization (ABO). Prior to NREL, Dr. Darzins led the protein engineering and high-throughput robotic screening effort at Promega Corp. Dr. Darzins began his career as a faculty member in the Department of Microbiology at The Ohio State University. He holds a Ph.D. in Microbiology and Immunology from the University of Illinois at Chicago.
Email Al Darzins
Holly has managed the finances for Proteos since 2007, and has over 20 years of financial accounting and tax experience. Prior to joining Proteos, she held positions of increasing management responsibilities with several small businesses in the West Michigan area. She is a graduate of Western Michigan University with a bachelor of business administration degree in accounting and management (Magna Cum Laude). Holly is also an active volunteer in community activities.
Email Holly Kehoe
Mary Shuck, leads a team of cell and molecular biologists responsible for all aspects of protein production in mammalian and insect cell systems. Prior to joining Proteos in 2009, Mary spent 20 years working in Discovery Research for Pfizer and legacy companies, Pharmacia, and Upjohn, where she focused on identification and pharmacological characterization of G-protein coupled receptors, ion channels, efflux transporters, enzymes and second messengers for programs in Neurobiology, Inflammation, Cardiovascular Diseases, and Osteoporosis. She earned special recognition awards for her pioneering work on the establishment of stable cell lines expressing G-protein coupled receptors (GPCRs) and ion channels and for the development of a novel cell based-efflux assay to assess the activity of the breast cancer resistance protein (BCRP). Early in her career, Mary worked at St. Jude Children’s Research Hospital in Memphis, TN in the Departments of Virology and Molecular Biology., studying immunoglobulin heavy chain gene rearrangements in patients with acute lymphoblastic leukemia (ALL). She holds a BS in Biology, cum laude from Bethel University in McKenzie, TN.
Email Mary Shuck
Lindsey Gottler, Ph.D., leads a team of protein scientists and oversees all bacterial expression and customized protein purification projects. Prior to joining Proteos in 2008, Dr. Gottler completed a post-doctoral fellowship at the University of Michigan in Biophysical Chemistry where she performed biophysical characterization of amyloidogenic peptides including amyloid beta and SEVI peptide. Lindsey received her Ph.D. in chemistry from the University of Michigan. Her studies included design of recombinant protein constructs for assembling non-natural, high order protein structures and study of synthetic peptides, both de novo designed and naturally occurring antimicrobial peptides, to evaluate the effects of non-natural, fluorous amino acids on protein stability, structure and function.
Email Lindsey Gottler